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Abstract 42 
Patients with primary aldosteronism (PA) have increased risk of target organ damage, 43 
among which vascular calcification is an important indicator of cardiovascular 44 
mortality. 14, 15-epoxyeicosatrienoic acid (14, 15-EET) has been shown to have 45 
beneficial effects in vascular remodeling. However, whether 14, 15-EET associates 46 
with vascular calcification in PA is unknown. Thus, we aimed to investigate the 47 
association between 14, 15-EET and abdominal aortic calcification (AAC) in patients 48 
with PA. 69 patients with PA and 69 controls with essential hypertension, matched for 49 
age, sex, and blood pressure, were studied. 14, 15-dihydroxyeicosatrienoic acid (14, 50 
15-DHET), the inactive metabolite from 14, 15-EET, was estimated to reflect serum 51 
14, 15-EET levels. AAC was assessed by computed tomographic scanning. Compared 52 
with matched controls, the AAC prevalence was almost one-fold higher in patients 53 
with PA [27 (39.1%) vs. 14 (20.3%), P = 0.023], accompanied by significantly higher 54 
serum 14, 15-DHET levels [(7.18 ± 4.98) vs. (3.50 ± 2.07) ng/mL, P < 0.001]. Plasma 55 
aldosterone concentration was positively associated with 14, 15-DHET (β =0.444, P < 56 
0.001). Multivariable logistic analysis revealed that lower 14, 15-DHET was an 57 
independent risk factor for AAC in PA (odds ratio [95% confidence interval], 1.371 58 
[1.145-1.640], P < 0.001), especially in young patients with mild hypertension and 59 
normal body mass index. In conclusion, PA patients exhibit more severe AAC, 60 
accompanied by higher serum 14, 15-DHET levels. On the other hand, decreased 14, 61 
15-EET was significantly associated with AAC prevalence in PA patients, especially 62 
in those at low cardiovascular risk. 63 
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Introduction 66 
Primary aldosteronism (PA), characterized by autonomous aldosterone secretion and 67 
suppressed plasma renin activity (PRA), accounts for 5%-13% of resistant 68 
hypertension and accordingly is not common in the clinic. Patients with PA are at 69 
increased risk of target organ damage, especially cardiac and renal complication.1,2 70 
Cardiovascular diseases (CVD) are the leading causes of death in PA patients, which 71 
account for 50% mortality.3 Hypertension is an important risk factor for CVD. 72 
Effective antihypertensive medication or surgery prevents CVD in PA patients.4 73 
However, some PA patients still exhibit severe cardiovascular complications even 74 
with treatments.5 It indicates that some other nontraditional risk factors may be also 75 
involved in the development of CVD in PA patients.  76 
Vascular calcification (VC), especially abdominal aortic calcification (AAC), an 77 
important nontraditional risk factor, is associated with high risk of CVD. 6 Findings 78 
from our studies and others show that hyperaldosteronism is significantly associated 79 
with increased VC.7,8 It was reported that AAC served as independent risk factor of 80 
persistent hypertension in patients undergoing adrenalectomy.9 Thus, AAC may be 81 
another important indicator of CVD in PA patients and understanding the 82 
mechanisms of AAC is critical. Many factors such as inflammatory cytokines are 83 
closely related to VC development.10 Notably, vascular inflammation was commonly 84 
seen in PA patients and associated with pronounced vascular alterations.11 Identifying 85 
the key factors underlying inflammation will facilitate the development of targeted 86 
therapies for reducing CVD in PA population. 87 
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Metabolized from arachidonic acids, epoxyeicosatrienoic acids (EETs) are 88 
important anti-inflammatory factors, which have protective effects on cardiovascular 89 
homeostasis. There are four types of EETs, 5, 6-, 8, 9-, 11, 12-, 14, 15-EET, among 90 
which 14, 15-EET is of high concentration in vasculature and have the closest 91 
relationship with CVD.12 In patients with established coronary heart disease, 92 
increasing serum EET levels was associated with lower risk of CVD.13,14 The 93 
polymorphism of the soluble epoxide hydrolase (sEH) gene was a significant 94 
predictor of coronary artery calcification status even after adjusting for traditional risk 95 
factors15. Accumulating preclinical and epidemiologic evidence suggest that inhibition 96 
of sEH-mediated EET hydrolysis has various cardiovascular protective effects 97 
including anti-inflammation.16,17 As EETs are easily hydrolyzed and hard to detect 98 
directly, the levels of their metabolite, dihydroxyeicosatrienoic acids (DHETs), are 99 
commonly used to reflect EET levels, which are also reported to be closely associated 100 
with CVD.18,19 Therefore, in our study, we assessed 14, 15-DHET as an indirect 101 
measure of 14, 15-EET levels.  102 
Pre-clinical studies showed that the aldosterone infusion in rats increased sEH 103 
protein expression in renal cortex and microvasculature. Aldosterone treatment of 104 
endothelial cells also significantly increased mRNA expression of sEH.20 In 105 
deoxycorticosterone acetate (DOCA)-salt treated mice, a model that mimics 106 
hyperaldoteronism, we demonstrated that the level of 20-hydroxyeicosatetraenoic acid 107 
was significantly reduced and further contributed to increased sodium retention and 108 
blood pressure.21 This phenomenon indicated that excess aldosterone secretion 109 
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inhibited EET production. However, whether downregulation of 14, 15-EET is 110 
associated with vascular damage in patients with PA is unknown. Thus, we conducted 111 
a case-control clinical study to measure serum 14, 15-DHET and investigated its role 112 
in AAC in patients with PA. 113 
Methods 114 
The authors declare that all supporting data are available within the article. 115 
Study population 116 
This was a single-center, case-controlled study conducted in Sun Yat-sen memorial 117 
hospital of Sun Yat-sen University. From January 2013 to June 2015, a total of 117 118 
patients suspicious of PA who were admitted to our unit, 20 patients who did not meet 119 
the following inclusion criteria or met the exclusion criteria were excluded. And we 120 
also excluded 28 patients missing the data of computerized tomography (CT) or 121 
serum biomedical tests. Baseline clinical and biochemical data were extracted from 122 
the hospital database.  123 
Inclusion of PA cases and EH controls were those who met the diagnostic criteria as 124 
detailed below. Patients with clinical/or laboratory evidence of associated conditions  125 
were excluded from this study, such as: (1) administration of any antihypertensive 126 
drugs within two weeks before recruitment; (2) recent infection inflammatory 127 
disorders, or hormonal replacement therapies; (3) history of chronic kidney diseases, 128 
hepatic diseases, rheumatologic diseases or malignancy including adrenocortical 129 
carcinoma.  130 
This study protocol conformed to the ethical guidelines of the 1975 Declaration of 131 
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Helsinki by the Ethics Committee of Sun Yat-sen University, and written informed 132 
consent was obtained from every study participants. 133 
Our screening methods and diagnostic criteria for PA and EH were in accordance 134 
with the current guideline.22 After withdrawal of medication influencing the 135 
renin-aldosterone system, patients were screened for PA using PAC to PRA 136 
[aldosterone-to-renin ratio (ARR), ng/L per ng/mL/h], with a cutoff of 25ng/L per 137 
ng/mL/h in the standing position. Diagnosis of PA was confirmed by the failure of 138 
aldosterone suppression after the oral sodium loading test (24-hour urinary 139 
aldosterone concentration≥10μg/24h) and captopril test (PAC≥130ng/L) as previously 140 
described.22,23  141 
During the same period, patients with EH were included when meeting the 142 
following criteria: a known history of hypertension with anti-hypertensive drugs 143 
treatment; and/or three documented office systolic blood pressure (SBP) ≥ 140 mmHg 144 
and /or diastolic blood pressure (DBP) ≥ 90 mmHg at different days; secondary forms 145 
of hypertension were excluded by reviewing records for medical history, physical 146 
examination, and appropriate biochemical tests and imaging studies. Notably, only 147 
patients who had a normal ARR were included as EH controls. In the present study, 148 
patients with PA and EH controls were 1:1 individually matched for age (± 3 years), 149 
gender and blood pressure (± 5mmHg) were included as controls. 150 
Multi-detector CT analysis of abdominal aorta  151 
All patients underwent an adrenal CT scan to evaluate abdominal aortic plaques. The 152 
plaques occupied by calcified tissue more than 50% of the plaque area (an area ≥ 1 153 
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mm2 with density of > 130 HU) were classified as calcified plaques (CPs).24 All 154 
imaging procedures were done on the same equipment using the same parameters. To 155 
measure AAC, the CT images were reconstructed in a 35 cm field of view with a slice 156 
thickness of 1 mm. All the scans were read by the SIEMENS Syngo CT Workplace at 157 
the same radiological department in our unit, and calcification in the distal abdominal 158 
aorta above the aortic bifurcation was used for analysis. AAC Agatston score was 159 
calculated by multiplying each CP area volumes by a weighted score assigned to the 160 
highest density of calcification (1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 161 
HU, 4 for 400 HU and greater) within the individual CP area. According to the AAC 162 
score, patients were grouped as having no detectable AAC (Agatston score = 0), mild 163 
(1-100), and severe (> 100) AAC as previously described.25 All the abdominal arterial 164 
datasets were analyzed by two blinded and experienced investigators.  165 
14, 15-DHET measurements  166 
Peripheral venous blood samples were collected from each recruited patient at 7:00 167 
a.m. before patients had the breakfast. After repeating the procedures of acidification, 168 
extraction and saponification for three times, we pooled all the organic phase (ethyl 169 
acetate) together and evaporated under argon gas. Then, we dissolved the dried 170 
residue of each sample in a minimal amount of ethanol (~20uL). An enzyme-linked 171 
immunosorbent assay (ELISA) was used to measure the plasma 14, 15-DHET (14, 172 
15-DHET ELISA kit; Detroit R&D Inc., Detroit, MI, USA) according to the manual.26 173 
Laboratory testing 174 
Blood samples were drawn between 08:00 a.m. and 11:00 a.m. after at least two-hour 175 
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upright posture, usually after they had been seated for 5-15min. Aldosterone in plasma 176 
and urine were measured by radioimmunoassay using a commercial kit Diagnostic 177 
Products (DSL, Texas, USA). The intra- and inter-assay coefficients of variation for 178 
PAC were 4.5% and 9.8%, respectively, and the reference range was 38.1-313.3 ng/L. 179 
Plasma renin activity (PRA) as the generation of angiotensin I in vitro was determined 180 
as previously described. The intra- and inter-assay coefficients of variation for PRA 181 
were 5.6% and 10%, respectively, and the reference range was (2.63 ± 1.32) ng/mL/h. 182 
Biochemical parameters, potassium, calcium (Ca), phosphorus (Pi), creatinine, 183 
alkaline phosphatase (ALP), fasting plasma glucose, HbA1c, triglyceride (TG), total 184 
cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density 185 
lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (Hs-CRP), 186 
urinary albumin excretion rate (UAER) were analyzed using a standardized and 187 
certified TBA-120 auto-analyzer (Toshiba Medical Systems, Japan) in the institutional 188 
central laboratory. Estimated glomerular filtration rate (eGFR) was calculated using 189 
the Chronic Kidney Disease Epidemiology Collaboration equation with modified 190 
coefficients for the Chinese population.27  191 
Statistical analysis 192 
Continuous variables with a normal distribution were reported as mean (± SD), 193 
skewed data as median (interquartile range). Categorical variables were presented as 194 
numbers (percentages). Baseline variables between patients with PA and matched EH 195 
were compared using paired Student’s t-test, Wilcoxon sign test or McNemar test 196 
according to the types of variables. Correlation analysis and linear regression analysis 197 
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was used to explore the factors affecting serum 14, 15-DHET levels and AAC severity 198 
in PA patients. Univariate and multivariate logistic analysis were used to investigate 199 
the association between serum 14, 15-DHET and AAC scores as well as in further 200 
subgroup analysis. Data were expressed as the odds ratio (OR) and 95% confidence 201 
interval (CI). Subgroup analysis was divided according to the cardiovascular risk 202 
factors affecting AAC.28 Data were analyzed with SPSS version 20 (SPSS, Inc, 203 
Chicago, Illinois, USA), and two-side P values less than 0.05 were considered 204 
statistically significant. 205 
Results 206 
Baseline characteristics of the study population 207 
The clinical and biochemical characteristics of 69 patients with PA caused by 208 
aldosterone-producing adenomas and 69 EH controls are shown in Table 1. Patients 209 
with PA had higher PAC, ARR and lower PRA, serum potassium than matched EH 210 
patients (all P < 0.05). Patients with PA showed lower BMI, accompanied by lower 211 
serum levels of LDL-C, HDL-C and TG (all P < 0.05). In contrast, UAER and urinary 212 
aldosterone were significantly higher in PA patients than that in controls (both P < 213 
0.05). However, no significant difference was found in the other biochemical 214 
parameters (serum Ca, Pi, TC, creatinine, ALP, Hs-CRP, fasting plasma glucose, 215 
HbA1c and eGFR) between these two groups. Of interest, patients with PA had a 216 
higher prevalence of abdominal aortic CPs than matched EH controls [27 (39.1%) vs. 217 
14 (20.3%), P = 0.023]. Moreover, the degree of AAC tended to be more severe in PA 218 
patients than EH patients [no AAC: mild AAC: severe AAC, (60.9%: 20.3%: 18.8%) 219 
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vs. (79.7%: 14.5%: 5.8%), P = 0.002] (Table 1). 220 
Risk factors of serum 14, 15-DHET in PA patients 221 
As shown in Figure. 1, serum 14, 15-DHET levels were significantly higher in 222 
patients with PA than matched EH controls [(7.18 ± 4.98) vs. (3.50 ± 2.07) ng/mL, P < 223 
0.001]. Notably, PA characteristic factors, including serum potassium or PRA, showed 224 
no significant relationship with serum 14, 15-DHET (Figure S1 and Figure S2 in the 225 
online-only Data Supplement). In order to explore whether LnPAC was an 226 
independent possible risk factors influencing 14, 15-DHET in PA, multiple linear 227 
regression analysis was used. We found that LnPAC was an independent risk factor of 228 
increased serum 14, 15-DHET after adjustment for age, BMI, SBP, DBP and serum 229 
lipid profiles (β = 0.444, P < 0.001) (Table 2). 230 
Association between serum 14, 15-DHET and AAC scores in patients with PA 231 
To evaluate the relationship between serum 14, 15-DHET and AAC scores in patients 232 
with PA, we measured serum levels of 14, 15-DHET in PA patients with different 233 
levels of AAC. As shown in Figure. 2A, serum 14, 15-DHET levels progressively 234 
increased as the severity of AAC increased [Median 5.01 vs. 6.37 vs. 15.09 ng/mL, in 235 
no AAC, mild AAC, severe AAC group, respectively, P < 0.001]. Moreover, serum 14, 236 
15-DHET levels were significantly associated with AAC scores in patients with PA (r 237 
= 0.593, P < 0.001; Figure. 2B).  238 
Identifying the PA population with high-risk of AAC  239 
As shown in Table 3, 14, 15-DHET was significantly associated with increased risk 240 
of AAC on univariate analysis (OR = 1.329, 95% CI 1.153-1.532, P < 0.001). This 241 
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association remained after adjusting for age, SBP, Ca, Pi, ALP, LDL-C, Hs-CRP, and 242 
eGFR (OR = 1.371, 95% CI 1.145-1.640, P < 0.001). In order to explore the specific 243 
PA patients with increased risk of AAC induced by 14, 15-EET alteration, we 244 
performed subgroup analysis based on traditional risk factors. As shown in Figure. 3, 245 
we found that the positive association between serum 14, 15-DHET level and AAC 246 
extent was significant in PA patients with age less than 50 years (OR = 1.552, 95% CI 247 
1.116-2.158, P = 0.009), mild hypertension (OR = 1.530, 95% CI 1.158-2.020, P = 248 
0.003) and normal BMI (OR = 1.320, 95% CI 1.063-1.639, P = 0.012). However, the 249 
association between 14, 15-DHET and AAC in PA was not significant in gender 250 
subgroups (both P > 0.05). 251 
Discussion 252 
Major findings from our study demonstrate that 1) patients with PA exhibit more 253 
frequent and more severe AAC compared with matched EH controls. 2) increased 254 
serum 14, 15-DHET, which possibly associates with excess PAC, is an independent 255 
risk factor for AAC, especially in PA patients with age younger than 50 years with 256 
normal BMI and SBP lower than 160mmHg. 257 
Target organ damage in PA patients is a major cause of cardiovascular 258 
complications worldwid.29 Thus, early diagnosis and appropriate control of risk 259 
factors of CVD is critical for PA patients. By comparing PA patients with matched 260 
controls, our study revealed that VC might be a novel important risk factor for PA 261 
patients beyond blood pressure elevation. As a nontraditional indicator for CVD, VC 262 
has been reported to be associated with increased risk of CVD.6 So exploring the 263 
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possible mechanisms of VC has caused great attention. Instead of passive calcium and 264 
phosphate precipitation previous thought, VC is now thought to be an actively 265 
regulated process.30 Many factors may contribute to the development of VC, among 266 
which chronic inflammation is a key player.31,32 In humans, focal arterial 267 
inflammation, as quantified by 18F-fluorodeoxyglucose/positron emission tomography, 268 
was suggested to precede calcification within the same locations.33 Fish oils, such as 269 
eicosapentaenoic acid, inhibited osteoblastic differentiation in vascular smooth 270 
muscle cells as well as VC through anti-inflammatory effects on nuclear factor-κB.34 271 
In support this, our study revealed that low anti-inflammatory 14, 15-EET, reflected 272 
by high 14, 15-DHET levels, was an independent risk factor of AAC in PA patients. 273 
Therefore, suppressing inflammation by increasing EETs may be cardiovascular 274 
protective and reduce the risk of VC in PA patients. 275 
Produced and generated from endothelial cells, EETs possess potent vasodilatory 276 
and anti-inflammatory effects in maintaining vascular homeostasis.35 It was reported 277 
some isoforms of EETs (such as 11, 12-EET) except for 14, 15-EET might induce 278 
vasoconstriction when cyclooxygenases/prostaglandins signaling was altered.36 279 
However, our study patients had no history of taking non-steroidal drugs, which is 280 
known to influence prostaglandins balance. It still warrants further investigation to 281 
identify this issue. Clinical studies have demonstrated that increasing EET levels have 282 
utility as a cardioprotective therapeutic strategy in coronary heart diseases, stroke, 283 
diabetes, et al.37-39 Many factors influence EET metabolism, including obesity, age 284 
and serum lipids. In obese individuals with coronary heart disease, increased body 285 
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mass was significantly associated with low plasma EET levels and 14, 15-EET/14, 286 
15-DHET ratio.14 Increasing EET levels by sEH inhibitors also had 287 
anti-atherosclerotic effects, which was associated with LDL-C reduction and HDL-C 288 
elevation.26,40 But in PA patients, we observed that excess PAC was independently 289 
associated with higher serum 14, 15-DHETs after adjustment for these traditional risk 290 
factors. In DOCA-salt mice, production of 20-hydroxyeicosatetraenoic acid was 291 
reduced.21 Clinical studies revealed that abnormal activation of the 292 
renin-angiotensin-aldosterone system might be the main reason for altered production 293 
of EETs by increasing sEH expression.35 Our study also showed that excess PAC was 294 
associated with decreased 14, 15-EET levels in PA patients. 295 
Another interesting result of our study was the association between serum 14, 296 
15-DHET levels and the extent of AAC. This was especially evident in younger PA 297 
patients with mild hypertension and normal BMI. These data suggest that in low-risk 298 
PA patients,28 downregulation of 14, 15-EET may trigger AAC formation in the early 299 
stage. This may explain why older PA patients with severe hypertension, and 300 
abnormal nutrition, 14, 15-EET showed no effect on AAC. With a series of traditional 301 
cardiovascular risks, AAC in patients PA became advanced and severe, even 302 
increasing EETs could not bring further benefits to AAC regression. However, further 303 
investigation was still required to verify our results. 304 
This study has several limitations that should be highlighted. Firstly, since the 305 
prevalence of PA is low in the Chinese population,41 the number of PA patients 306 
enrolled in the study was relatively small. Therefore, further studies with larger 307 
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sample size are needed to verify our findings. Secondly, due to the cross-sectional 308 
design of the present study, causality between plasma 14, 15-DHET levels and AAC 309 
extent can not be established despite adjustment for possible factors. Thirdly, 310 
angiotensin II (Ang II) was not measured in our study, Ang II can upregulate EET 311 
production and thereby complicate interpretation.42 However, overproduction of 312 
aldosterone is the characteristic feature of PA patients, and changes in levels of Ang II 313 
and changes in levels of angiotensin II may be inhibited because of the negative 314 
feedback, this may be difficult to assess. Further studies are needed to unravel this 315 
aspect. Fourthly, it was not possible to obtain vascular tissue for direct measurement 316 
of sEH activity, thus we measured 14, 15-DHET to reflect serum 14, 15-EET levels.26 317 
Finally, high-performance liquid chromatography was a standard method for 318 
quantifying cytochrome P450-derived eicosanoid metabolite concentrations.43 In this 319 
present study, we used a simpler method, ELISA to specifically measure serum 14, 320 
15-DHET levels. However, the results from both methods were proven to be 321 
comparable.21  322 
In conclusion, we provide clinical evidence that patients with PA have significantly 323 
higher AAC compared with matched EH controls. Downregulaiton of 14, 15-EET is 324 
probably an important predictor of AAC in patients with PA, especially in younger PA 325 
patients with mild hypertension and normal BMI.  326 
Perspectives 327 
Our findings suggest that downregulated serum 14, 15-EET is closely with an 328 
increase of AAC in patients with PA. Therefore, measuring serum 14, 15-DHET, a 329 
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surrogate marker of 14, 15-EET, may provide a valuable additional tool for future 330 
AAC evaluation in PA. 331 
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 495 
Novelty and Significance 496 
What Is New? 497 
 Primary aldosteronism (PA) is an important cause of secondary hypertension 498 
with exaggerated target organ damage. We provide evidence that 499 
hyperaldosteronism is a risk factor of abdominal aortic calcification (AAC) 500 
and identify novel predictors.  501 
 We show an association between 14, 15-epoxyeicosatrienoic acid (14, 502 
15-EET) and AAC in PA patients. 503 
What Is Relevant? 504 
 Our findings define a new marker for target organ damage, specifically AAC, 505 
in PA patients. 506 
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 Decreased 14, 15-EET is significantly associated with AAC in PA patients. 507 
Summary 508 
We demonstrated for the first time that patients with PA had a high risk of AAC. 509 
Notably, low levels of anti-inflammatory 14, 15-EET, reflected by high 14, 15-DHET 510 
levels, was an independent risk factor of AAC in PA patients. New strategies to 511 
increase the anti-inflammatory EET may be cardiovascular protective and prevent 512 
AAC in patients with PA, especially in younger patients with mild hypertension and 513 
normal body mass index.  514 
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Figure legends  515 
Figure 1. Comparison of serum 14, 15-DHET levels between patients with PA 516 
and EH. Each black dot referred to one patient. The middle horizontal line 517 
represented median values, 25th and 75th quartiles were shown as the lower and the 518 
upper line. 14, 15-DHET, 14, 15-dihydroxyeicosatrienoic acid; EH, essential 519 
hypertension; PA, primary aldosteronism. 520 
Figure 2. The correlation between serum 14, 15-DHET levels and AAC scores in 521 
PA patients. A, The serum level of 14, 15-DHET in different degree of AAC groups. 522 
We found that the serum 14, 15-DHET levels were gradually elevated with AAC 523 
severity increased. Boxplots showing median values (horizontal line inside the box), 524 
quartiles (box boundaries), and the largest and smallest observed values (lines drawn 525 
from the end of the box) *P < 0.05 vs. no AAC group; **P < 0.05 vs. mild AAC group. 526 
B, Spearman correlation analysis showed that the serum levels of 14, 15-DHET were 527 
significantly associated with the AAC scores. (r = 0.593; P < 0.001). AAC, abdominal 528 
aortic calcification; 14, 15-DHET, 14, 15-dihydroxyeicosatrienoic acid; PA, primary 529 
aldosteronism. 530 
Figure 3. Subgroup analysis of assessing the association between serum 14, 531 
15-DHET and AAC score in PA. Multivariate logistic analysis after adjustment for 532 
Ca, Pi, ALP, LDL-C, Hs-CRP, and eGFR was perform in subgroup according to age 533 
(less than 50y or over than 50y), sex (male or female), SBP (less than 160mmHg or 534 
over than 160mmHg), BMI (20-25kg/m2 or over than 25kg/m2). Data were expressed 535 
as the odds ratio and 95% confidence interval. AAC, abdominal aortic calcification; 536 
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ALP, alkaline phosphatase; BMI, body mass index; Ca, calcium; 14, 15-DHET, 14, 537 
15-dihydroxyeicosatrienoic acid; eGFR, estimated glomerular filtration rate; Hs-CRP, 538 
high-sensitivity-C-reactive protein; LDL-C, low density lipoprotein cholesterol; Pi, 539 
phosphate; SBP, systolic blood pressure; PA, primary aldosteronism. 540 
